After decades of research there is now a plethora of cell-based therapies traversing through different phases of clinical trials. However, there remains work to be done regarding optimising the quality and production efficiency of these therapies, as well as economic considerations to validate their commercial viability. This project focuses on the process development of a candidate human embryonic stem cell (hESC) based therapy for Parkinson's disease (PD) and the related health economics. This work set out to identify the key translational requirements for successful, robust and reproducible manufacture of a cell-based therapy for PD, by optimising a preclinical validated differentiation protocol.